Your browser doesn't support javascript.
loading
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.
Rossignol, Patrick; Agarwal, Rajiv; Canaud, Bernard; Charney, Alan; Chatellier, Gilles; Craig, Jonathan C; Cushman, William C; Gansevoort, Ronald T; Fellström, Bengt; Garza, Dahlia; Guzman, Nicolas; Holtkamp, Frank A; London, Gerard M; Massy, Ziad A; Mebazaa, Alexandre; Mol, Peter G M; Pfeffer, Marc A; Rosenberg, Yves; Ruilope, Luis M; Seltzer, Jonathan; Shah, Amil M; Shah, Salim; Singh, Bhupinder; Stefánsson, Bergur V; Stockbridge, Norman; Stough, Wendy Gattis; Thygesen, Kristian; Walsh, Michael; Wanner, Christoph; Warnock, David G; Wilcox, Christopher S; Wittes, Janet; Pitt, Bertram; Thompson, Aliza; Zannad, Faiez.
Afiliación
  • Rossignol P; Inserm, Centre d'Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; Université de Lorraine; Association Lorraine pour le Traitement de l'Insuffisance Rénale, Institut lorrain du Cœur et des Vaisseaux Louis Mathieu, 4 rue du Morvan, Nancy, France.
  • Agarwal R; F-CRIN INI-CRCT, Nancy, France.
  • Canaud B; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Charney A; Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.
  • Chatellier G; Fresenius Medical Care Deutschland and University of Montpellier, UFR Medicine, France.
  • Craig JC; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Cushman WC; AP-HP, Hôpital Européen Georges Pompidou, Unité de Recherche Clinique and INSERM CIC 1418, Paris, France.
  • Gansevoort RT; School of Public Health, The University of Sydney, New South Wales, Australia.
  • Fellström B; Centre for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia.
  • Garza D; Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee, USA.
  • Guzman N; Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Holtkamp FA; Inserm U1018, Université Paris-Saclay, UVSQ, Université. Paris-Sud, Villejuif, France.
  • London GM; Relypsa, Inc., Redwood City, CA, USA.
  • Massy ZA; AstraZeneca, Gaithersburg, MD, USA.
  • Mebazaa A; Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
  • Mol PGM; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Pfeffer MA; F-CRIN INI-CRCT, Nancy, France.
  • Rosenberg Y; France Centre Hospitalier F.H. Manhès, Fleury-Merogis, France.
  • Ruilope LM; F-CRIN INI-CRCT, Nancy, France.
  • Seltzer J; Ambroise Pare University Hospital, APHP, Paris-Ile-de France-Ouest University (UVSQ), and INSERM U1018, Team 5 Boulogne Billancourt, France.
  • Shah AM; F-CRIN INI-CRCT, Nancy, France.
  • Shah S; U942 Inserm, Paris, France.
  • Singh B; University Paris Diderot, Sorbonne Paris Cité, Paris, France.
  • Stefánsson BV; APHP, Department of Anesthesia and Critical Care, Hôpitaux Universitaires Saint Louis-Lariboisière, Paris, France.
  • Stockbridge N; Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
  • Stough WG; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Thygesen K; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Walsh M; National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
  • Wanner C; Institute of Investigation and Hypertension Unit, Hospital 12 de Octubre, Department of Preventive Medicine and Public Health, Universidad Autonoma and School of Doctoral Studies and Research, Universidad Europea de Madrid, Madrid, Spain.
  • Warnock DG; ACI Clinical, Bala Cynwyd, PA, USA.
  • Wilcox CS; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Wittes J; Sarfez Pharmaceuticals, Inc., McLean, VA, USA.
  • Pitt B; ZS Pharma, San Mateo, CA, USA.
  • Thompson A; AstraZeneca, Gothenburg, Sweden.
  • Zannad F; Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Eur Heart J ; 40(11): 880-886, 2019 03 14.
Article en En | MEDLINE | ID: mdl-28431138
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Insuficiencia Renal Crónica / Fallo Renal Crónico Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Heart J Año: 2019 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Insuficiencia Renal Crónica / Fallo Renal Crónico Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur Heart J Año: 2019 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido